People taking DMT tended to experience significant relief from their depression for up to three months, the researchers found ...
Breakthrough study finds single dose of psychedelics significantly reduced depression symptoms in clinical trial, with ...
Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...
In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.
Gadget Review on MSN
Magic mushroom treatment takes a big step toward FDA approval – here's what changed
Compass Pathways' synthetic psilocybin COMP360 clears Phase 3 trials, showing 39% depression reduction in 24 hours for treatment-resistant patients.
Vermont Business Magazine Psychiatric Services at Rutland Regional Medical Center have begun to treat patients suffering from depression with a new medication-free process known as NeuroStar® Advanced ...
F OR FIVE years biotech startups have been betting that psychedelic substances could be turned into real medicines. One of them may have hit the jackpot. On February 17th Compass ...
For the first time, Americans with depression will soon be able to use a prescription brain-stimulation device at home. The approval comes from the U.S. Food and Drug Administration and marks a major ...
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Jessica Mendoza: A quick heads up before we get started. This episode mentions ...
The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results